News
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
October 20, 2021
Recro Reports Inducement Grants For New Staff
October 6, 2021
Recro Signs Renewable Energy Agreement With Georgia Power
September 21, 2021
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 8, 2021
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
August 13, 2021
Recro Reports Second Quarter 2021 Financial Results
August 9, 2021
Recro Reports Inducement Grants for New Staff
July 7, 2021
Recro Reports Inducement Grants for New Staff
April 6, 2021
Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
April 5, 2021
Recro Reports Fourth Quarter and Year End 2020 Financial Results
February 26, 2021
Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
February 23, 2021
Recro Announces Amendment to Athyrium Credit Facility
February 23, 2021
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
February 19, 2021
Recro Grants Inducement Award to New Chief Executive Officer
December 18, 2020
Recro Announces Executive Changes
December 16, 2020
Recro Reports Third Quarter 2020 Financial Results
November 9, 2020
Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
November 2, 2020
Recro Reports Second Quarter 2020 Financial Results
August 10, 2020
Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
August 6, 2020
Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
May 11, 2020
Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020
May 8, 2020
Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
May 1, 2020
COVID-19
March 19, 2020
Recro Reports Financial Results for the Year Ended 2019
March 4, 2020
Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
March 2, 2020
Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization
November 21, 2019
Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
November 21, 2019
Recro Pharma Reports Third Quarter 2019 Financial Results
November 8, 2019
Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019
November 5, 2019
Recro Pharma Reports Second Quarter 2019 Financial Results
August 8, 2019
Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
August 1, 2019
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro
April 16, 2019
Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
April 3, 2019
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
March 22, 2019
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
March 4, 2019
Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
February 25, 2019
Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
February 20, 2019
Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
February 14, 2019
Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro
February 11, 2019
Recro Pharma Amends Athyrium Credit Facility
January 2, 2019
Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
December 21, 2018
Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology
December 10, 2018
Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia
November 14, 2018
Recro Pharma to Participate in Upcoming Investor Conferences
November 8, 2018
Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018
November 7, 2018
Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
October 31, 2018
Recro Pharma Announces PDUFA Date for IV Meloxicam
October 8, 2018
Recro Announces Expansion of CDMO Service Capabilities
October 1, 2018
Recro Pharma to Participate in Upcoming Investor Conferences
September 10, 2018
Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018
September 5, 2018
Recro Pharma Provides Regulatory Update for IV Meloxicam
September 4, 2018
Recro Pharma Reports Second Quarter 2018 Financial Results
August 7, 2018
Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
July 31, 2018
Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam
May 7, 2018
Recro Pharma Announces Commercial Team Additions
May 2, 2018
Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
April 30, 2018
Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
April 16, 2018
Recro Pharma Announces Commercial Team Additions
March 29, 2018
Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain
March 27, 2018
Recro Pharma to Present at Upcoming Investor Conferences
March 6, 2018
Recro Pharma Announces Commercial Team Additions
March 2, 2018
Recro Pharma Reports Year End 2017 Financial Results
February 27, 2018
Recro Pharma to Host Analyst and Investor Day on February 28, 2018
February 21, 2018
Recro Pharma to Host Analyst and Investor Day on February 28, 2018
February 21, 2018
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
February 20, 2018
Recro Pharma Announces Key Sales Team Additions
February 2, 2018
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology
January 17, 2018
Recro Pharma Reports Inducement Grants for New Staff
December 29, 2017
Recro Pharma Secures $100 Million Credit Facility
November 20, 2017
Recro Pharma Reports Third Quarter 2017 Financial Results
November 9, 2017
Recro Pharma to Present at Upcoming Investor Conferences
November 8, 2017
Recro Pharma Reports Inducement Grants for New Staff
October 31, 2017
Recro Pharma to Participate in Upcoming Investor Conferences
October 5, 2017
Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg
October 5, 2017
Recro Pharma Reports Inducement Grants for New Staff
September 29, 2017
Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg
September 28, 2017
Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017
September 5, 2017
Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development
August 21, 2017
Recro Pharma Reports Inducement Grants for New Staff
August 10, 2017
Recro Pharma Reports Second Quarter 2017 Financial Results
August 10, 2017
Recro Pharma Reports Inducement Grants for New Staff
July 21, 2017
Recro Pharma Reports Inducement Grants for New Staff
July 10, 2017
Recro Pharma Added to the Russell 3000® Index
June 26, 2017
Recro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference
June 16, 2017
Recro Pharma Reports Inducement Grants for New Staff
June 15, 2017
Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer
June 6, 2017
Recro Expands Manufacturing Capabilities
May 24, 2017
Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
May 9, 2017
Recro Pharma Reports Year End 2016 Financial Results
March 6, 2017
Recro Pharma to Present at Upcoming Investor Conferences
March 2, 2017
Recro Pharma Announces Pricing of Public Offering of Common Stock
December 13, 2016
Recro Pharma Announces Proposed Public Offering of Common Stock
December 8, 2016
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
November 28, 2016
Recro Pharma Reports Third Quarter 2016 Financial Results
November 10, 2016
Recro Pharma to Present at Upcoming Investor Conferences
November 9, 2016
Recro Pharma Presents Clinical Data at PAINWeek 2016
September 7, 2016
Recro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 6, 2016
Recro Pharma Announces Proposed Public Offering of Common Stock
August 15, 2016
Recro Pharma Reports Second Quarter 2016 Financial Results
August 11, 2016
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
July 26, 2016
Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
May 12, 2016
Recro Pharma Reports Year End 2015 Financial Results
March 24, 2016
Recro Pharma Appoints Fred Graff as Chief Commercial Officer
February 16, 2016
Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
February 1, 2016
Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
January 27, 2016
Recro Pharma to Present at NobleCon12 Investor Conference
January 14, 2016
Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
January 6, 2016
Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
December 2, 2015
Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
November 24, 2015
Recro Pharma Reports Third Quarter 2015 Financial Results
November 13, 2015
Recro Pharma to Participate in Upcoming Investor Conferences
November 12, 2015
Recro Pharma Provides Pipeline Update
October 26, 2015
Recro Pharma Appoints Karen A. Flynn to Its Board of Directors
September 10, 2015
Recro Pharma Announces Presentations at PAINWeek 2015
September 10, 2015
Recro Pharma Reports Second Quarter 2015 Financial Results
August 14, 2015
Recro Pharma Appoints Scott Rizzo as General Manager
July 20, 2015
Recro Pharma Announces Positive Top-Line Results for Phase II Clinical Trial of Dex-IN
July 17, 2015
Recro Pharma Completes $16 Million Private Financing
July 7, 2015
Recro Pharma Announces $16 Million Financing
July 1, 2015
Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes
April 13, 2015
Recro Pharma to Acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing Facility and Business Unit From Alkermes
March 9, 2015
Recro Pharma Reports Third Quarter 2014 Financial Results
November 10, 2014
Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
October 29, 2014
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
September 4, 2014
Recro Pharma Reports Second Quarter 2014 Financial Results
August 12, 2014
Recro Pharma Added to Russell Microcap(R) Index
June 30, 2014
Recro Pharma Announces New Board Members
March 13, 2014
Recro Pharma Announces Closing of Initial Public Offering
March 12, 2014